STSA-1005 injection gains approval from the U.S. FDA to conduct clinical trials
Michael Strainic2021-09-22T12:10:39-08:00STSA-1005 injection gains approval from the U.S. FDA to conduct clinical trials Staidson BioPharma Inc., a wholly-owned subsidiary of Staidson (Beijing) Biopharmaceutical Co., Ltd. received a notification from the Food and Drug Administration (FDA) approving the use of STSA-1005 injection for clinical trials in the treatment of severe COVID-19 indications.